Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from AdAlta Ltd. ( (AU:1AD) ) is now available.
AdAlta Ltd. has announced a renounceable pro rata rights offer to its shareholders in Australia and New Zealand, allowing them to acquire new shares and attaching options. This offer leads to an adjustment in the exercise price of existing options, reflecting the company’s strategic move to raise capital and potentially enhance shareholder value.
More about AdAlta Ltd.
AdAlta Ltd. is a biotechnology company focused on developing innovative therapies using its proprietary i-body technology. The company operates primarily in the pharmaceutical industry, targeting unmet medical needs with a focus on novel biologic drugs.
Average Trading Volume: 801,102
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.22M
See more insights into 1AD stock on TipRanks’ Stock Analysis page.